SEC Filing | T2 Biosystems Inc.

Names of Reporting Persons

Nathan D. Hukill

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☒ (1) (b) ☐

SEC Use Only

Citizenship or Place of Organization

United States

View:

Download DOC

Download PDF

Download XLS

SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

T2 Biosystems, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

89853L203

(CUSIP Number)

July 3, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 89853L203		Page 2 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)

This percentage is calculated based on 290,195,720 shares of Common Stock issued and outstanding as of July 3, 2023, as provided by the Issuer, plus 24,157,794 shares of Common Stock issuable upon conversion of shares of Series B convertible preferred stock of the Issuer that are beneficially owned by the Reporting Persons.


CUSIP No. 89853L203		Page 3 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)


CUSIP No. 89853L203		Page 4 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)	This percentage is calculated based on 290,195,720 shares of Common Stock issued and outstanding as of July 3, 2023, as provided by the Issuer.


CUSIP No. 89853L203		Page 5 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)	This percentage is calculated based on 290,195,720 shares of Common Stock issued and outstanding as of July 3, 2023, as provided by the Issuer.


CUSIP No. 89853L203		Page 6 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)	This percentage is calculated based on 290,195,720 shares of Common Stock issued and outstanding as of July 3, 2023, as provided by the Issuer.


CUSIP No. 89853L203		Page 7 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)


CUSIP No. 89853L203		Page 8 of 14

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

(2)


CUSIP No. 89853L203		Page 9 of 14


Item 1.

	(a)	Name of Issuer T2 Biosystems, Inc.

	(b)	Address of Issuer’s Principal Executive Offices 101 Hartwell Avenue, Lexington, MA 02421

Item 2.

	(a)	Name of Person Filing This Schedule 13G is filed jointly by the following persons (each a “Reporting Person” and collectively, the “Reporting Persons”): Nathan D. Hukill CR Group L.P. CRG Partners III L.P. CRG Partners III Parallel Fund “A” L.P. CRG Partners III (Cayman) Unlev AIV I L.P. CRG Partners III (Cayman) Lev AIV I L.P. CRG Partners III Parallel Fund “B” (Cayman) L.P.
		CR Group L.P. may be deemed to beneficially own the shares by virtue of its position as the investment manager for CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. Mr. Hukill may be deemed to have beneficial ownership over the securities by virtue of his indirect control of CR Group L.P.

	(b)	Address of Principal Business Office or, if none, Residence The address of the principal business office of each of the Reporting Persons is 1000 Main Street, Suite 2500, Houston, TX 77002.

	(c)	Citizenship See Row 4 of the cover page for each Reporting Person.

	(d)	Title of Class of Securities Common Stock, par value $0.001 per share

	(e)	CUSIP Number 89853L203

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable


CUSIP No. 89853L203		Page 10 of 14


Item 4.	Ownership

	(a)	Amount beneficially owned:

		Nathan D. Hukill	72,503,592 (1)
		CR Group L.P.	72,503,592 (1)
		CRG Partners III L.P.	19,334,277
		CRG Partners III Parallel Fund “A” L.P.	12,039,660
		CRG Partners III (Cayman) Unlev AIV I L.P.	3,866,855
		CRG Partners III (Cayman) Lev AIV I L.P.	37,262,800 (1)
		CRG Partners III Parallel Fund “B” (Cayman) L.P.	24,157,794 (1)

	(b)	Percent of class:

		Nathan D. Hukill	19.9% (2)
		CR Group L.P.	19.9% (2)
		CRG Partners III L.P.	6.7% (2)
		CRG Partners III Parallel Fund “A” L.P.	4.1% (2)
		CRG Partners III (Cayman) Unlev AIV I L.P.	1.3% (2)
		CRG Partners III (Cayman) Lev AIV I L.P.	12.8% (2)
		CRG Partners III Parallel Fund “B” (Cayman) L.P.	8.3% (2)

	(c)	Number of shares as to which the person has:

		(i) Sole power to vote or to direct the vote:

		Nathan D. Hukill	0
		CR Group L.P.	0
		CRG Partners III L.P.	0
		CRG Partners III Parallel Fund “A” L.P.	0
		CRG Partners III (Cayman) Unlev AIV I L.P. CRG Partners III (Cayman) Lev AIV I L.P.	0 0
		CRG Partners III Parallel Fund “B” (Cayman) L.P.	0

		(ii) Shared power to vote or to direct the vote:

		Nathan D. Hukill	72,503,592 (1)
		CR Group L.P.	72,503,592 (1)
		CRG Partners III L.P.	19,334,277
		CRG Partners III Parallel Fund “A” L.P.	12,039,660
		CRG Partners III (Cayman) Unlev AIV I L.P.	3,866,855
		CRG Partners III (Cayman) Lev AIV I L.P.		37,262,800	(1)
		CRG Partners III Parallel Fund “B” (Cayman) L.P.		24,157,794	(1)

		(iii) Sole power to dispose or to direct the disposition of:

		Nathan D. Hukill		0
		CR Group L.P.		0
		CRG Partners III L.P.		0
		CRG Partners III Parallel Fund “A” L.P.		0
		CRG Partners III (Cayman) Unlev AIV I L.P. CRG Partners III (Cayman) Lev AIV I L.P.		0 0
		CRG Partners III Parallel Fund “B” (Cayman) L.P.		0


CUSIP No. 89853L203		Page 11 of 14



		(iv) Shared power to dispose or to direct the disposition of:

		Nathan D. Hukill	72,503,592	(1)
		CR Group L.P.	72,503,592	(1)
		CRG Partners III L.P.	19,334,277
		CRG Partners III Parallel Fund “A” L.P.	12,039,660
		CRG Partners III (Cayman) Unlev AIV I L.P.	3,866,855
		CRG Partners III (Cayman) Lev AIV I L.P.	37,262,800	(1)
		CRG Partners III Parallel Fund “B” (Cayman) L.P.	24,157,794	(1)

	(1)	Includes 24,157,794 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock.

	(2)	This percentage is calculated based on 290,195,720 shares of Common Stock issued and outstanding as of July 3, 2023, as provided by the Issuer, plus 24,157,794 shares of Common Stock issuable upon conversion of shares of Series B convertible preferred stock of the Issuer that are beneficially owned by the Reporting Persons.

Item 5.	Ownership of Five Percent or Less of a Class

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not applicable



Item 8.		Identification and Classification of Members of the Group

		Not applicable

Item 9.		Notice of Dissolution of Group

		Not applicable

Item 10.		Certification

		By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.


CUSIP No. 89853L203		Page 12 of 14

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 13, 2023

Nathan D. Hukill

/s/ Nathan D. Hukill

An individual

CR Group L.P.

CRG Partners III L.P.

CRG Partners III Parallel Fund “A” L.P.

CRG Partners III (Cayman) Unlev AIV I L.P.

CRG Partners III (Cayman) Lev AIV I L.P.

CRG Partners III Parallel Fund “B” (Cayman) L.P.


By:		/s/ Nathan D. Hukill
		Nathan D. Hukill, authorized signatory


CUSIP No. 89853L203		Page 13 of 14

EXHIBITS


A:		Joint Filing Agreement

EX-99.A


CUSIP No. 89853L203		Page 1 4 of 14

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of T2 Biosystems, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 13th day of July, 2023.